From 2 Years to 61: How CF Life Expectancy Was Transformed - and Why the Fight Isn't Over

In the 1960s, a child diagnosed with cystic fibrosis was not expected to reach elementary school. The disease was essentially a pediatric death sentence - a genetic disorder that destroyed the lungs slowly, relentlessly, and for which medicine had no real answer. Parents were given a diagnosis and a timeframe measured in years.

Today, the projected median survival for someone born with CF is 61 years.

That is not a rounding error. That is one of the most dramatic transformations of any genetic disease in the history of medicine - and it happened within a single lifetime. Understanding how it happened, and why the fight still isn't over, is essential context for why CF Bites Foundation exists.

How We Got Here: The Arc of CF Treatment

Progress in CF has not been linear. It has come in waves, each one driven by a new scientific understanding of the disease.

The first wave - through the 1970s and 1980s - focused on managing symptoms: airway clearance therapies, nutritional support, antibiotics for the chronic lung infections that are the primary cause of CF mortality. These interventions didn't fix CF. They bought time. And that time mattered enormously - it extended lives long enough for the next wave to arrive.

The second wave came with genetic research. In 1989, scientists identified the CFTR gene - the gene responsible for CF. That discovery set the research community on a path toward understanding exactly what goes wrong at the molecular level. It would take decades to translate that understanding into drugs, but the direction was set.

The third wave - the one that changed the numbers - was CFTR modulators. Ivacaftor (2012), Orkambi (2015), Symdeko (2018), Trikafta (2019), and now ALYFTREK (2024). Each drug reached more patients and produced more dramatic results. Trikafta alone has been described as the most transformative drug development in CF history - reducing hospitalizations by 75%, improving lung function significantly, and changing the daily reality of life with CF for hundreds of thousands of patients.

What the Numbers Actually Represent

When we say median survival is now 61 years, that number reflects a population average. Some CF patients will live much longer. Some will face complications that shorten their lives. And crucially, that number is a projection - it reflects expected outcomes for people born today, based on the treatments currently available. As better treatments arrive, the number will continue to rise.

There are approximately 40,000 people living with CF in the United States. More than 1,000 new diagnoses occur each year. Each of those people is living in a world where CF science is moving faster than at any point in history.

Why the Fight Isn't Over

Progress is real. But there are still approximately 2,000–4,000 CF patients in the U.S. who cannot access CFTR modulators - because their specific mutation doesn't respond. There are patients with advanced lung disease for whom the drugs arrived too late to prevent significant damage. There are children in lower-income countries where access to Trikafta and ALYFTREK remains limited by cost.

And there is no cure yet. A 61-year median survival is extraordinary compared to where this disease began. It is not the finish line.

What CF Bites Is Funding

CF Bites Foundation raises money for the Cystic Fibrosis Foundation - the organization that has funded more than 50% of every CF therapy brought to market, including Trikafta. The CFF's research pipeline right now includes gene therapy, mRNA approaches, improved antibiotic strategies, and next-generation modulators that could reach the patients current drugs miss.

Taylor Lentz founded CF Bites because her daughter Aubin was diagnosed with CF, and because Taylor - a nurse who had cared for CF patients - understood exactly what was at stake. She understood that the 61-year number didn't happen by accident. It happened because for decades, people showed up.

That's what every CF Bites gala is about. That's what every jar war, every witches ride, every ticket sold represents: one more push toward a number that keeps getting better. We're not done. We're nowhere near done. But look at how far we've come.